UNIVERSITY HOSPITALS OF DERBY & BURTON NHS FOUNDATION TRUST DRUG MONOGRAPH FOR USE ON ADULT INTENSIVE CARE UNITS

Acetylcysteine (Nebulisation)

Indication	Mucolytic	
Dose	600mg QDS	
Preparation	Ampoules contain 2000mg in 10ml (200mg per ml) Draw up 3ml (600mg) into a syringe	
Administration	 For nebuliser use only Recommended procedure: 1. Give a salbutamol 2.5mg nebule, then wait 3 – 5 minutes 2. Give acetylcysteine, then wait 30minutes 3. Give Sodium chloride 0.9% 5ml nebule 	
Shelf-life	Use immediately	
Common Compatibility Issues	Not applicable as a nebulised product	
Additional information	 Acetylcysteine is not licensed for use as a mucolytic. Licensed formulations for enteral administration are available (carbocisteine capsules and liquid.) The current evidence is that carbocisteine is equivalent to acetylcysteine therefore consider carbociseteine if a long term mucolytic is indicated. If effective can loosen a large volume of mucous so may require increased suctioning. Acetylcysteine can cause bronchospasm hence the need for the salbutamol prior to administration. Acetylcysteine has a bad odour. 	
Sample Label	Not required as prepared for nebulisation	

Documentation Controls

Development of Guideline:	Pharmacist – Critical Care & Theatres
Consultation with:	Pharmacy Department
Approved By:	ICU Sister's Meeting: June 2023
	ICU Risk & Quality Meeting: August 2023
	Surgical Division
Review Date:	June 2025
Key contact:	Pharmacist – Critical Care & Theatres

References

Brayfield A (ed), Martindale: The Complete Drug Reference. [online] London: Pharmaceutical Press <<u>http://www.medicinescomplete.com/</u>> (accessed February 2022).

*** End of Monograph ***